Critical care of acute ischemic stroke.

被引:6
作者
Bernstein R.A. [1 ]
Hemphill J.C. [1 ]
机构
[1] Department of Neurology, San Francisco General Hospital, 4M62, Room, 1001 Potrero Avenue, San Francisco, 94110, CA
关键词
Ischemic Stroke; Single Photon Emission Compute Tomography; Acute Stroke; Acute Ischemic Stroke; Abciximab;
D O I
10.1007/s11910-001-0066-y
中图分类号
学科分类号
摘要
Advances in neurologic therapeutics and intensive care medicine have expanded the arsenal of treatments available for the critical care of ischemic stroke. Several agents are available for acute reperfusion of the ischemic brain. These include intravenous recombinant tissue-plasminogen activator (rtPA), which is effective in a 3-hour time window, and intra-arterial thrombolytics, which may be effective within 6 hours. In addition, newer agents such as Ancrod and abciximab may be effective within the acute time period. Efforts to prevent secondary brain injury in critically ill patients with stroke often include prevention and reduction of fever, induced hypertension, and mechanical ventilation. Finally, death due to severe brain edema after massive hemispheric infarction can often be prevented with surgical or medical intervention. Unfortunately, there is a critical lack of well-designed clinical studies to guide the clinician in the use of these interventions. In addition, there is concern that some of these interventions may preserve life at the cost of quality of life. This article reviews the evidence behind these approaches to the critical care of ischemic stroke.
引用
收藏
页码:587 / 592
页数:5
相关论文
共 87 条
[1]  
DeGraba TJ(2000)Why do neuroprotective drugs work in animals but not humans? Neurol Clin 19 475-493
[2]  
Pettigrew LC(1995)Tissue plasminogen activator for acute ischemic stroke N Engl J Med 333 1581-1587
[3]  
Albers GW(2000)Intravenous tissuetype plasminogen activator for treatment of acute stroke: the standard treatment with alteplase to reverse stroke (STARS) study JAMA 283 1145-1150
[4]  
Bates VE(1998)Randomized doubleblind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II) Lancet 352 1245-1251
[5]  
Clark WM(1999)Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset JAMA 282 2019-2026
[6]  
Hacke W(1999)Intra-arterial prourokinase for acute ischemic stroke JAMA 282 2003-2011
[7]  
Kaste M(1999)Intra-arterial thrombolysis for perioperatve stroke after open heart surgery Neurology 52 1081-1084
[8]  
Fieschi C(2000)Intra-arterial thrombolysis for the treatment of perioperative childhood cardioembolic stroke Neurology 54 1684-1686
[9]  
Clark WM(1998)Angioplasty after intra-arterial thrombolysis for acute occlusion of intracranial arteries Stroke 29 2568-2574
[10]  
Wissman S(2000)Timing of recanalization after tissue plasminogen activator therapy determined by transcranial doppler correlates with clinical recovery from ischemic stroke Stroke 31 1812-1816